Table 3.
Association of the MSH2 rs4608577 polymorphisms and PFS in lung cancer patients
| Gene | Polymorphism | Genotype | MPFS (year) | Additive | Dominant | Recessive | |||
|---|---|---|---|---|---|---|---|---|---|
| OR (95%CI) | p value | OR (95%CI) | p value | OR (95%CI) | p value | ||||
| MSH2 | rs4608577 | GG | 7.97 | 0.94 (0.33-1.57) | 0.003** | 0.94 (0.27-1.61) | 0.006** | 2.48 (-0.20-5.17) | 0.071 |
| GT | 4.94 | ||||||||
| TT | 2.67 | ||||||||
MPFS, median progression-free survival; OR, odds ratio; CI, confidence interval; Additive model: comparison between minor allele subjects and major allele subjects. Dominant model: comparison between minor allele carriers and major homozygous subjects. Recessive model: comparison between major allele carriers and minor homozygous subjects. ** P < 0.01.